SCHEMBL2621812

SCHEMBL2621812

CN1CC[C@@H](COc2ccnc3ccc(Br)cc23)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 6/20 0.46
▸ FGFR1 P11362 5/20 0.46
▸ FLT1 P17948 5/20 0.46
▸ FLT4 P35916 5/20 0.46
▸ KDR P35968 5/20 0.46
▸ RET P07949 3/20 0.46
▸ HTT P42858 3/20 0.46
▸ ROCK2 O75116 2/20 0.46
▸ CDC42BPB Q9Y5S2 2/20 0.46
▸ PDGFRB P09619 2/20 0.46
▸ TEK Q02763 2/20 0.46
▸ IRAK4 Q9NWZ3 2/20 0.46
▸ BMPR1B O00238 1/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ CIT O14578 1/20 0.46
▸ GAK O14976 1/20 0.46
▸ EPHB6 O15197 1/20 0.46
▸ RIPK2 O43353 1/20 0.46
▸ STK10 O94804 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19723307 1.00 EGFR (0.46) EGFRFGFR1FLT1FLT4KDR
SCHEMBL2621811 1.00 EGFR (0.46) EGFRFGFR1FLT1FLT4KDR
SCHEMBL2621797 0.83 HCRTR1 (0.52) KDRHTTERBB2EPHA2EPHB4
SCHEMBL2621821 0.82 PDPK1 (0.47) EGFRFGFR1FLT1FLT4KDR
SCHEMBL5501482 0.81 IRAK4 (0.49) IRAK4GAKEPHB6RIPK2ABL1
SCHEMBL2621822 0.79 ROCK2 (0.47) EGFRFGFR1FLT1FLT4KDR
SCHEMBL2621800 0.79 HCRTR1 (0.50) EGFRHTTIRAK4GAKEPHB6
SCHEMBL2621813 0.79 IRAK4 (0.46) IRAK4GAKEPHB6RIPK2ABL1
SCHEMBL2621810 0.77 IRAK4 (0.54) IRAK4PDPK1
SCHEMBL2621815 0.75 IRAK4 (0.48) IRAK4PDPK1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560967-B1 Heterocyclic carboxylic acid amides as PDK1 inihibitors BOEHRINGER INGELHEIM INT (DE) 2017-12-20 — — EP disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-8575203-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed
US-20120094976-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094976-A1 NEW CHEMICAL COMPOUNDS CCNB1, MKI67, CCNA1 EGFR 1504/4885FGFR1 408/4885FLT1 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback